Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD.

Aquaporin 4 Autoantibodies BNT162 Vaccine COVID-19 / prevention & control COVID-19 Vaccines Humans Immunoglobulin G Myelin-Oligodendrocyte Glycoprotein Neuromyelitis Optica Recurrence Retrospective Studies SARS-CoV-2 Vaccination
AQP4 MOG MOGAD NMOSD SARS-CoV-2 Vaccination

Journal

Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247

Informations de publication

Date de publication:
Feb 2022
Historique:
received: 16 10 2021
revised: 16 11 2021
accepted: 20 11 2021
entrez: 26 2 2022
pubmed: 27 2 2022
medline: 3 3 2022
Statut: ppublish

Résumé

Post-vaccination disease relapses have been reported in patients with MOGAD and AQP4-IgG+NMOSD. In this retrospective multicenter Italian study we assessed the frequency of relapses after SARS-CoV-2 vaccination. We included 56 cases: MOGAD, 30; AQP4-IgG+NMOSD, 26. Vaccines received were BNT162b2-Pfizer-BioNTech in 42 patients and mRNA-1273-Moderna in 14 patients. Six patients had a history of SARS-CoV-2 infection; two of them experienced a post-infection disease relapse (MOGAD). The frequency of relapses within one month of SARS-CoV-2 vaccination was 4% (1/26) in the AQP4-IgG+NMOSD group and 0% in the MOGAD group. In these patients the potential benefits of vaccination overcome the risk of relapses.

Identifiants

DOI: 10.1016/j.msard.2021.103424 PMID: 35216793 PMC: PMC8607690
pubmed: 35216793
pii: S2211-0348(21)00690-8
doi: 10.1016/j.msard.2021.103424
pmc: PMC8607690
pii:
doi:

Substances chimiques

Aquaporin 4 0
Autoantibodies 0
COVID-19 Vaccines 0
Immunoglobulin G 0
Myelin-Oligodendrocyte Glycoprotein 0
BNT162 Vaccine N38TVC63NU

Types de publication

Letter Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

103424

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Références

J Neurol Neurosurg Psychiatry. 2021 Aug 18;:
pubmed: 34408003
Mult Scler Relat Disord. 2018 Jul;23:78-82
pubmed: 29783157
Ann Neurol. 2021 Feb;89(2):408-413
pubmed: 33210746
Neurology. 2021 Sep 14;97(11):e1097-e1109
pubmed: 34261784
Mult Scler Relat Disord. 2022 Jan;57:103320
pubmed: 35158424
Neurol Neuroimmunol Neuroinflamm. 2021 Aug 24;8(5):
pubmed: 34429342
Int J MS Care. 2020 Mar-Apr;22(2):85-90
pubmed: 32410903
Mult Scler Relat Disord. 2022 Jan;57:103321
pubmed: 35158439
Mult Scler Relat Disord. 2021 Oct;55:103189
pubmed: 34375861

Auteurs

Alessandro Dinoto (A)

Neurology Unit, Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Italy.

Elia Sechi (E)

Department of Medical, Surgical and Experimental Sciences, University of Sassari, Italy.

Sergio Ferrari (S)

Neurology Unit, Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Italy.

Alberto Gajofatto (A)

Neurology Unit, Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Italy.

Riccardo Orlandi (R)

Neurology Unit, Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Italy.

Paolo Solla (P)

Department of Medical, Surgical and Experimental Sciences, University of Sassari, Italy.

Alessandra Maccabeo (A)

Department of Medical, Surgical and Experimental Sciences, University of Sassari, Italy; Department of Medical Sciences and Public Health, University of Cagliari, Italy.

Giorgia Teresa Maniscalco (GT)

Department of Neurology and Stroke Unit "A. Cardarelli Hospital", Naples, Italy.

Vincenzo Andreone (V)

Department of Neurology and Stroke Unit "A. Cardarelli Hospital", Naples, Italy.

Arianna Sartori (A)

Neurology Unit, Department of Medical, Surgical and Health Sciences, Cattinara University Hospital, ASUGI, University of Trieste, Trieste, Italy.

Paolo Manganotti (P)

Neurology Unit, Department of Medical, Surgical and Health Sciences, Cattinara University Hospital, ASUGI, University of Trieste, Trieste, Italy.

Sarah Rasia (S)

Multiple Sclerosis Center, ASST - Spedali Civili of Brescia, Montichiari, Brescia, Italy.

Ruggero Capra (R)

Multiple Sclerosis Center, ASST - Spedali Civili of Brescia, Montichiari, Brescia, Italy.

Chiara Rosa Mancinelli (CR)

Multiple Sclerosis Center, ASST - Spedali Civili of Brescia, Montichiari, Brescia, Italy.

Sara Mariotto (S)

Neurology Unit, Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Italy. Electronic address: sara.mariotto@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Protéines de transport membranaire › Canaux ioniques › Porines › Aquaporines › Aquaporine-4 › Risk of disease relapse following COVID-19...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Autoanticorps › Risk of disease relapse following COVID-19...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Vaccins synthétiques › Vaccins à base d'acide nucléique › Vaccins à ARNm › Vaccin BNT162 › Risk of disease relapse following COVID-19...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Risk of disease relapse following COVID-19...
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins antiviraux › Vaccins contre la COVID-19 › Risk of disease relapse following COVID-19...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Risk of disease relapse following COVID-19...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Isotypes des immunoglobulines › Immunoglobuline G › Risk of disease relapse following COVID-19...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Autoantigènes › Glycoprotéine MOG › Risk of disease relapse following COVID-19...
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Maladies auto-immunes du système nerveux › Maladies démyélinisantes auto-immunes du SNC › Neuromyélite optique › Risk of disease relapse following COVID-19...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Récidive › Risk of disease relapse following COVID-19...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Risk of disease relapse following COVID-19...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › Risk of disease relapse following COVID-19...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Pratiques en santé publique › Prévention primaire › Immunisation › Vaccination › Risk of disease relapse following COVID-19...